PF-07265028 is a selective inhibitor of hematopoietic progenitor kinase 1 (HPK1) with Ki<0.05 nM and represents >280-fold improvement in biochemical potency while maintaining a comparable lipophilicity.

YK-2168 is a differentiated selective CDK9 inhibitor with IC50 of 5.9 nM, demonstrating 72.5-fold and 45.2-fold selectivity over CDK1 and CDK2, respectively. YK-2168 achieves superior CDK9 selectivity over AZD4573 and comparable selectivity to BAY1251152.

Ferfluor-1 is a novel 1,3,4-thiadiazole-functionalized druglike ferrostatin analogue as a ferroptosis inhibitor and photoluminescent indicator. Ferfluor-1 shows superior anti-ferroptosis potency, favorable BBB permeability and in vivo activity against stroke and Parkinson's disease.

P6CIT is a cationic lipid for targeted mRNA delivery to pancreatic ductal adenocarcinoma (PDAC). Pan-tgt (P6CIT) LNP could specifically deliver mRNA to immune cells in PDAC tissues, including dendritic cells (DCs), macrophages, natural killer (NK) cells, and T cells.

VIP36 is a peripherally restricted cannabinoid receptor type 1 (CB1) agonist with Ki of 22 nM and exerts analgesic efficacy through peripheral CB1 receptors and shows limited analgesic tolerance.

YEATS4 binder 4e stands out as a highly potent and selective small-molecule inhibitor targeting the epigenetic reader YEATS4. It demonstrates a strong binding affinity with a Ki value of 37 nM. Importantly, this compound exhibits remarkable selectivity, showing over 15-fold preference for YEATS4 compared to other members of the YEATS family, including YEATS1, YEATS2, and YEATS3.

Idactamab (INT-001) is an IgG1-κ antibody with in vivo activity across a spectrum of hematological malignancies. Idactamab can be used for prepare MEDI7247, a potent and specific ADC, targeting ASCT2 (SLC1A5).

Elotuzumab is a monoclonal antibody directed against the SLAMF7 receptor. Elotuzumab has no significant antimyeloma activity when given as a single agent with relapsed or refractory multiple myeloma (RRMM). Elotuzumab results in improved response and outcome when combined with other antimyeloma agents.

Azintuxizumab is an anti-SLAMF7 human IgG4κ monoclonal antibody. Azintuxizumab can be used in the synthesis of antibody-drug conjugate (ADC), Azintuxizumab vedotin.

KWAR23 is an anti-human SIRPα antibody. KWAR23 binds human SIRPα with high affinity and disrupts its binding to CD47. KWAR23 shows antitumor activity in combination with tumor-opsonizing antibodies and can be used in cancer immunotherapy research.

Lirentelimab (AK002) is a humanized IgG1 monoclonal antibody that targets sialic acid-binding Ig-like lectin 8 (SIGLEC8). Lirentelimab induces cell apoptosis of IL-5-activated eosinophils and inhibits IgE-mediated mast cell activation. Lirentelimab can be used for the research of eosinophilic gastritis and duodenitis.

Refanezumab (GSK249320) is an IgG1-type humanized monoclonal antibody directed against myelin-associated glycoprotein (MAG). Refanezumab binds to MAG and blocks MAG-mediated inhibition of axonal regeneration. Refanezumab can cross the blood-brain barrier (BBB) in animal stroke models. Refanezumab has the potential for the enhancement of recovery of function poststroke.

Gemtuzumab is a monoclonal IgG4-κ antibody targeting CD33 antigen, which present on leukemic myeloblasts of acute myeloid leukemia (AML). Gemtuzumab can be used for synthesis of antibody-drug conjugate (ADC), Gemtuzumab ozogamicin (HY-109539). Gemtuzumab ozogamicin consists of a cytotoxic derivative of Calicheamicin (a cytotoxic antibiotic), and a monoclonal antibody. Gemtuzumab ozogamicin can be used for the research of acute myeloid leukemia.

Vadastuximab is a humanized monoclonal antibody targeting CD33. Vadastuximab can be used to synthesize an ADC compound, Vadastuximab talirine.

Pinatuzumab is a CD22 monoclonal antibody. Pinatuzumab targets the cell-surface antigen CD22. Pinatuzumab can be used for synthesis of antibody agent conjugates (ADCs) to research several diseases including non-Hodgkin lymphoma (NHL).

Epratuzumab (Antibody hLL 2) is an anti-CD22 IgG1 monoclonal antibody. Epratuzumab is also a tumor-imaging agent and an immunomodulatory agent. Epratuzumab can induce CD22 phosphorylation. Epratuzumab has been used to research non-Hodgkin’s lymphomas (NHL) and certain autoimmune diseases.